SG11201503989PA - Computationally optimized broadly reactive antigens for h1n1 influenza - Google Patents

Computationally optimized broadly reactive antigens for h1n1 influenza

Info

Publication number
SG11201503989PA
SG11201503989PA SG11201503989PA SG11201503989PA SG11201503989PA SG 11201503989P A SG11201503989P A SG 11201503989PA SG 11201503989P A SG11201503989P A SG 11201503989PA SG 11201503989P A SG11201503989P A SG 11201503989PA SG 11201503989P A SG11201503989P A SG 11201503989PA
Authority
SG
Singapore
Prior art keywords
influenza
reactive antigens
broadly reactive
computationally optimized
optimized broadly
Prior art date
Application number
SG11201503989PA
Inventor
Ted M Ross
Jr Donald M Carter
Corey J Crevar
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of SG11201503989PA publication Critical patent/SG11201503989PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
SG11201503989PA 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza SG11201503989PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730186P 2012-11-27 2012-11-27
PCT/US2013/072279 WO2014085616A1 (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza

Publications (1)

Publication Number Publication Date
SG11201503989PA true SG11201503989PA (en) 2015-06-29

Family

ID=50773495

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503989PA SG11201503989PA (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza

Country Status (13)

Country Link
US (3) US9309290B2 (en)
EP (1) EP2925773B1 (en)
JP (2) JP2016505538A (en)
KR (1) KR20150089005A (en)
CN (1) CN104797594A (en)
AU (2) AU2013352179B2 (en)
CA (1) CA2891682A1 (en)
HK (1) HK1212708A1 (en)
IN (1) IN2015DN03070A (en)
MX (1) MX2015005056A (en)
RU (1) RU2015124805A (en)
SG (1) SG11201503989PA (en)
WO (1) WO2014085616A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (en) * 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Computationally optimized broadly reactive antigens for h1n1 influenza
US9212207B2 (en) 2012-03-30 2015-12-15 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses
JP6764408B2 (en) * 2014-12-19 2020-09-30 オレゴン ヘルス アンド サイエンス ユニバーシティー Synthetic combination of computer-optimized broad-reactive antigens for H1N1 influenza
AU2016274770B2 (en) * 2015-06-09 2020-11-12 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
SG11201810758WA (en) 2016-06-03 2018-12-28 Sanofi Pasteur Inc Modification of engineered influenza hemagglutinin polypeptides

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0111830B8 (en) * 2000-06-23 2021-05-25 American Cyanamid Co method of producing influenza virus-like particles (vlps), influenza vlps, chimeric vlps, immunogenic and pharmaceutical compositions, and uses of influenza vlps and chimeric vlps
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN101163714A (en) 2005-02-24 2008-04-16 马萨诸塞大学 Influenza nucleic acids, polypeptides, and uses thereof
WO2007011904A2 (en) 2005-07-19 2007-01-25 Dow Global Technologies Inc. Recombinant flu vaccines
CA2633793A1 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics S.R.L. Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
CN101877965B (en) * 2007-11-12 2014-08-20 宾夕法尼亚大学托管会 Novel vaccines against multiple subtypes of influenza virus
EA034733B1 (en) * 2008-01-21 2020-03-13 Медикаго Инк. Nucleic acid for increased expression of hemagglutinin of influenza virus in a plant and use thereof
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
DK2998315T4 (en) 2009-04-03 2022-02-07 Boehringer Ingelheim Animal Health Usa Inc NEWCASTLE DISEASE VIRUS-BORN BIRD VACCINES
AU2010265766B2 (en) * 2009-06-24 2015-03-19 Medicago Inc. Chimeric influenza virus-like particles comprising hemagglutinin
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
CN102373184A (en) * 2010-08-09 2012-03-14 中山大学 Avian influenza and infectious bronchitis hybrid virus-like particle as well as preparation method and application thereof
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (en) * 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Computationally optimized broadly reactive antigens for h1n1 influenza
US9234008B2 (en) 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
CA2863949C (en) 2012-02-13 2021-06-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
US9212207B2 (en) * 2012-03-30 2015-12-15 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses

Also Published As

Publication number Publication date
JP2018183149A (en) 2018-11-22
AU2013352179A1 (en) 2015-05-14
JP2016505538A (en) 2016-02-25
WO2014085616A1 (en) 2014-06-05
AU2018201876A1 (en) 2018-04-12
EP2925773A4 (en) 2016-06-08
US20160166677A1 (en) 2016-06-16
AU2013352179A8 (en) 2015-05-28
EP2925773A1 (en) 2015-10-07
MX2015005056A (en) 2015-07-23
RU2015124805A (en) 2017-01-13
CN104797594A (en) 2015-07-22
AU2013352179B2 (en) 2017-12-21
HK1212708A1 (en) 2016-06-17
US20170114102A1 (en) 2017-04-27
EP2925773B1 (en) 2018-12-26
KR20150089005A (en) 2015-08-04
IN2015DN03070A (en) 2015-10-02
US9566328B2 (en) 2017-02-14
US20140147459A1 (en) 2014-05-29
US10017544B2 (en) 2018-07-10
US9309290B2 (en) 2016-04-12
CA2891682A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
EP2721158A4 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
HK1203522A1 (en) Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses h5n1 h1n1
HK1202060A1 (en) Rna formulation for immunotherapy rna
HK1202442A1 (en) Vaccines against hpv hpv
EP2663334A4 (en) Antibodies directed against influenza
EP2616545A4 (en) Computationally optimized broadly reactive antigens for influenza
EP2768858A4 (en) Antibodies directed against influenza
HK1203523A1 (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza h5n1
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b
HK1212708A1 (en) Computationally optimized broadly reactive antigens for h1n1 influenza h1n1
IL231043A (en) Vaccine
GB201119999D0 (en) Vaccine
EP2763699A4 (en) Vaccine
ZA201306245B (en) Combination vaccines
EP2771453A4 (en) Diatom-based vaccines
ME03367B (en) Rna formulation for immunotherapy
EP2701735A4 (en) Liquid vaccine preparations
ZA201405107B (en) Mtb-c vaccine against asthma
ZA201404512B (en) Malaria vaccine
GB201120000D0 (en) Vaccine
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
GB201108982D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108984D0 (en) Vaccines